ANG Lifesciences India Limited
BSE: ANG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock ANG Lifesciences India Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
ANG Lifesciences India Limited is a pharmaceutical company specialising in the manufacturing and marketing of finished formulations, including sterile dry powder and liquid injectables. The company operates a significant facility in Baddi, Himachal Pradesh, and serves both as a contract research and manufacturing services provider and a branded generic player.
Business Model
The company generates revenue through contract manufacturing services for leading Indian pharmaceutical firms and the sale of its own branded generic products. It leverages strategic acquisitions of formulation units to expand production capacity and market reach.
Growth Outlook
Growth is driven by the expansion of manufacturing capabilities through strategic acquisitions and the strengthening of its domestic market presence. The company continues to focus on scaling its production of diverse therapeutic segments, including antibiotics and antivirals.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and potential regulatory inspections at its manufacturing facilities.
- Market Competition. Intense competition within the Indian pharmaceutical sector may exert pressure on pricing and profit margins for generic formulations.
- Operational Concentration. Reliance on a primary manufacturing facility in Baddi creates exposure to regional operational disruptions or supply chain bottlenecks.
- Raw Material Volatility. Fluctuations in the cost of active pharmaceutical ingredients and packaging materials can impact the company's cost of goods sold.
Start your research today
Unlock AI insights, financials, peers and live data on ANG Lifesciences India Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
ANG Lifesciences India LimitedANG | ₹40 Cr | — | — | — | 35.0% | — | — | +15.2% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
ANG Lifesciences India Limited
BSE: ANG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock ANG Lifesciences India Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
ANG Lifesciences India Limited is a pharmaceutical company specialising in the manufacturing and marketing of finished formulations, including sterile dry powder and liquid injectables. The company operates a significant facility in Baddi, Himachal Pradesh, and serves both as a contract research and manufacturing services provider and a branded generic player.
Business Model
The company generates revenue through contract manufacturing services for leading Indian pharmaceutical firms and the sale of its own branded generic products. It leverages strategic acquisitions of formulation units to expand production capacity and market reach.
Growth Outlook
Growth is driven by the expansion of manufacturing capabilities through strategic acquisitions and the strengthening of its domestic market presence. The company continues to focus on scaling its production of diverse therapeutic segments, including antibiotics and antivirals.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and potential regulatory inspections at its manufacturing facilities.
- Market Competition. Intense competition within the Indian pharmaceutical sector may exert pressure on pricing and profit margins for generic formulations.
- Operational Concentration. Reliance on a primary manufacturing facility in Baddi creates exposure to regional operational disruptions or supply chain bottlenecks.
- Raw Material Volatility. Fluctuations in the cost of active pharmaceutical ingredients and packaging materials can impact the company's cost of goods sold.
Start your research today
Unlock AI insights, financials, peers and live data on ANG Lifesciences India Limited and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026